Dr Vivek Mohan

Dr Vivek Mohan
Vivek
Mohan
Consultant Medical Oncologist

Languages spoken

English

Expert in

Breast cancer, cancer of unknown primary and non-specific but concerning symptoms for cancer

Overview

Centres

Bristol
Bristol
51.541807689358095, -2.5709663094294277
/uk/our-centres/bristol

Breast Cancer

Dr. Mohan has completed extensive training in the treatment of a wide variety of tumour sites at Oxford, Cambridge, Clatterbridge Centre for Oncology, and Nottingham. After completing oncology training, Dr. Mohan developed a special interest in treating patients with breast cancer and cancer of unknown primary (CUP).

As a breast oncology consultant at the Bristol Cancer Institute, Dr. Mohan has in-depth experience managing female and male patients with all stages of breast cancer for almost a decade. Dr. Mohan has extensive understanding and experience in treating patients with standard adjuvant, neo-adjuvant, and palliative chemotherapy, immunotherapy, and various targeted therapies such as anti-Her 2, PARP inhibitors, and CDK 4/6 inhibitor treatment.

Dr. Mohan is an active member of the breast cancer multi-disciplinary team meetings (MDT) and breast complex care meetings (CCM) at Bristol. Additionally, Dr. Mohan works very closely with the cancer psychology team to provide compassionate and comprehensive overall care and support for patients.

Cancer of unknown primary

Dr Mohan is the lead oncologist for CUP (cancer of unknown primary) at Bristol Cancer Institute and part of the CUP MDT at Bristol. Cancer of unknown primary is a rare diagnosis with a very poor outcome. As a consultant Medical Oncologist, Dr Mohan has been treating CUP patients at the Bristol Cancer Institute for approximately a decade. Patients with cancer of unknown primary are best to be referred urgently for diagnostic work up and an early start of treatment. 

Non-Specific but concerning symptoms for Cancer

As part of the process to detect cancer early, Dr Mohan has been the lead oncologist delivering the Non-specific but concerning symptom pathway for patients in Bristol and Weston between 2022-24 at the Bristol Cancer Institute.

 

Career Positions

Current position(s)

  • Consultant Medical Oncologist

Expertise and interests

  • Breast cancer
  • Cancer of Unkown Primary
  • Non-specific symptoms concerning for cancer

Professional associations

  • UK breast cancer group
  • Association of cancer physicians
  • Royal college of physicians
  • European society of medical oncologists

Publications & affiliations

1.    An unusual flare up of anti-synthetase syndrome during concurrent trastuzumab therapy given for recurrent breast cancer, Eur J Rheumatol 2017; 4: 278-80

2.    Abdel-Fatah TM, Russell R, Albarakati N, Maloney DJ, Dorjsuren D, Rueda OM, Moseley P, Mohan V, Sun H, Abbotts R, Mukherjee A, Agarwal D, Illuzzi JL, Jadhav A, Simeonov A, Ball G, Chan S, Caldas C, Ellis IO, Wilson DM 3rd, Madhusudan S. Genomic and protein expression analysis reveals flap endonuclease 1 (FEN1) as a key biomarker in breast and ovarian cancer (FEN1) as a key biomarker in breast and ovarian cancer. 

Mol Oncol. 2014 May 13. [Epub ahead of print] PMID: 24880630

3.    Sultana R, Abdel-Fatah T, Perry C, Moseley P, Albarakti N, Mohan V, Seedhouse  C, Chan S, Madhusudan S. Ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase inhibition is synthetically lethal in XRCC1 deficient ovarian cancer cells. PLoS One. 2013;8(2):e57098. doi: 10.1371/journal.pone.0057098. Epub 2013 Feb 25. PubMed PMID: 23451157; PubMed Central PMCID: PMC3581581

4.    Abdel-Fatah T, Arora A, Gorguc I, Abbotts R, Beebeejaun S, Storr S, Mohan V, Hawkes C, Soomro I, Lobo DN, Parsons SL, Madhusudan S. Are DNA Repair Factors Promising Biomarkers for Personalized Therapy in Gastric Cancer? Antioxid Redox Signal. 2012 Oct 19. [Epub ahead of print] PubMed PMID: 22894650.       

5.    Prematilleke I, Mohan V, Roberts I, Protheroe A, Gatter K. Blastic plasmacytoid dendritic cell neoplasm presenting as a renal mass. Histopathology.  2011 Oct;59(4):799-801. doi: 10.1111/j.1365-2559.2011.03953.x. Epub 2011 Sep 21. PubMed PMID: 21939455.

6.    Pulimood AB, Ramakrishna BS, Rita AB, Srinivasan P, Mohan V, Gupta S, Perakath B, Kang G, Chandy G, Balasubramanian KA. Early activation of mucosal dendritic cells and macrophages in acute Campylobacter colitis and cholera: An in vivo study. J Gastroenterol Hepatol. 2008 May;23(5):752-8. doi: 10.1111/j.1440-1746.2008.05325.x. PubMed PMID: 18410609.

7.    Ramakrishna BS, Subramanian V, Mohan V, Sebastian BK, Young GP, Farthing MJ, Binder HJ. A randomized controlled trial of glucose versus amylase resistant starch hypo-osmolar oral rehydration solution for adult acute dehydrating diarrhea. PLoS One. 2008 Feb 13;3(2):e1587. doi: 10.1371/journal.pone.0001587. PubMed PMID: 18270575; PubMed Central PMCID: PMC2217593.

8.    Venkataraman S, Mohan V, Ramakrishna BS, Peter S, Chacko A, Chandy G, Kurian G, Kurian S, Mathan M, Mathan VI, Patra S, Pulimood A, Rolston DD. Risk of colorectal cancer in ulcerative colitis in India. J Gastroenterol Hepatol. 2005 May;20(5):705-9. PubMed PMID: 15853982.

List of Book Chapter

1.    DNA Base Excision Repair: Evolving Biomarkers for Personalized Therapies in Cancer, Vivek Mohan and Srinivasan Madhusudan  http://dx.doi.org/10.5772/54607

http://www.intechopen.com/articles/show/title/dna-base-excision-repair-evolving-biomarkers-for-personalized-therapies-in-cancer